July 7 (Reuters) – Obesity-focused clinical-stage biotechnology company Kalohexis on Tuesday confidentially filed to go public in the U.S., adding to an activity rebound in the initial public offering market.
Terms of the offering were not yet determined, the company said.
Here are more details about the company:
• Kalohexis launched after spinning out of Endevica Bio in March, to advance the clinical development of its portfolio drug candidates. The Endevica Bio leadership team leads this new company.
• Kalohexis aims to treat metabolic disorders by targeting the body’s melanocortin (MC) system, a natural regulator of metabolic homeostasis.
• The company is developing a proprietary pipeline of peptides designed to safely target these central regulatory receptors.
• Its lead program, 710GO, is an oral dual MC3/MC4 receptor agonist intended to induce durable weight loss for general obesity.
• Additionally, the company is advancing mifomelatide, a dual MC3R/MC4R antagonist designed to combat cachexia, a severe wasting syndrome that can become life threatening, in patients with advanced cancers.
(Reporting by Pritam Biswas in Bengaluru; Editing by Shreya Biswas)
